Clarity in cell line development

Solentim in the Press: “Fast-Tracking Cell-Line Development”, BioCompare

“Protein pharmaceuticals represent a multibillion-dollar market, but deciphering the most suitable biotherapeutic-producing cell lines is a substantial manufacturing bottleneck”, writes Lauren Tanabe for a recent article published by BioCompare. CHO cells have been the expression system of choice for producing biological therapies for several decades; they are accepted by the FDA, easy to work with, …

Read more Solentim in the Press: “Fast-Tracking Cell-Line Development”, BioCompare

Removal of fluorescence screening of clones in cell line development: a paradigm shift

Dr Ian Taylor, Chief Commercial Officer, Solentim, blogs on his views following the recent ESACT conference in Copenhagen. Having just returned from ESACT in Copenhagen, I was impressed once again with the extremely high quality of the poster sessions throughout the event, presented by top level scientists working in labs around the world. One aspect …

Read more Removal of fluorescence screening of clones in cell line development: a paradigm shift

Postcard from BPI Europe in Vienna – Highlights of the Cell Line Development Stream

This annual meeting in early Spring is always a good forum for major new product and technology announcements. In previous years, discussions often mainly centred around assurance of clonality and the requirements of the FDA – still a key consideration for cell line development. Recently, however, the market has expanded from a focus on monoclonal …

Read more Postcard from BPI Europe in Vienna – Highlights of the Cell Line Development Stream

Important considerations for optimising outgrowth from single cells in cloning plates during cell line development

When developing biotherapeutics there are many parts of the process that require optimisation. Cell line development is a key part of this process and there are many aspects where changes can have a dramatic effect on timelines and outcomes. One key area which is challenging to many of our customers is outgrowth of clones in …

Read more Important considerations for optimising outgrowth from single cells in cloning plates during cell line development

Collaboration: changing CLD practices

In January 2019 Solentim, a global leader in cell line development (CLD) instrumentation, and bioengineering company ATUM, announced a technology partnering and collaboration agreement to enable rapid, high expression, stable cell line development. But what exactly are the tangible benefits gained from both parties and for customers, and why does this fusion of technology offer more …

Read more Collaboration: changing CLD practices

Finding the right balance: digital biology versus smart, transformative automation

In this latest blog by Solentim’s Dr Ian Taylor, the advent of digital biology is discussed. This is compared and contrasted with smarter automation, transformative new biology and better control over proven wet biology methods which have been developed and refined over decades. Many agree that this is the era of synthetic biology, smarter automation …

Read more Finding the right balance: digital biology versus smart, transformative automation